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Exposure to inflammatory cytokines selectively limits
GM-CSF production by induced T regulatory cells
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Richard A. O’Connor1 and Stephen M. Anderton1,2
1 MRC Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK
2 Centre for Immunity, Infection and Evolution, University of Edinburgh, Edinburgh, UK
Interest in manipulating the immunosuppressive powers of Foxp3-expressing T regula-
tory cells as an immunotherapy has been tempered by their reported ability to produce
proinflammatory cytokines when manipulated in vitro, or in vivo. Understanding
processes that can limit this potentially deleterious effect of Treg cells in a therapeutic
setting is therefore important. Here, we have studied this using induced (i) Treg cells
in which de novo Foxp3 expression is driven by TCR-stimulation in vitro in the pres-
ence of TGF-β. We show that iTreg cells can produce significant amounts of three
proinflammatory cytokines (IFN-γ, GM-CSF and TNF-α) upon secondary TCR stimulation.
GM-CSF is a critical T-cell derived cytokine for the induction of EAE in mice. Despite their
apparent capacity to produce GM-CSF, myelin autoantigen-responsive iTreg cells were
unable to provoke EAE. Instead, they maintained strong suppressive function in vivo,
preventing EAE induction by their CD4+Foxp3− counterparts. We identified that although
iTreg cells maintained the ability to produce IFN-γ and TNF-α in vivo, their ability to
produce GM-CSF was selectively degraded upon antigen stimulation under inflammatory
conditions. Furthermore, we show that IL-6 and IL-27 individually, or IL-2 and TGF-β in
combination, can mediate the selective loss of GM-CSF production by iTreg cells.
Keywords: Autoimmunity  Cytokines  Immunotherapy  Regulatory T cells  Treg cells
 Additional supporting information may be found in the online version of this article at thepublisher’s web-site
Introduction
The effective therapeutic use of Foxp3+ Treg cell populations
remains an important goal in the search for new treatments for
autoimmune and allergic conditions, as well as for imposing tol-
erance toward transplanted organs. Both natural (n)Treg-cell and
induced (i)Treg-cell populations have been shown to provide
potent protection in mouse models when transferred before or
after the onset of pathology [1–4]. However, both of these
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Foxp3+ populations have also been shown to be able to “trans-
differentiate” in vitro, producing proinflammatory cytokines fol-
lowing TCR stimulation in the presence of cytokines that drive
Th1 or Th17 differentiation [5–7]. Notably, subsets of human
Treg cells can also display a capacity for IFN-γ [8, 9] and IL-17
production [10–12] and experimental evidence suggests that the
trans-differentiation of Treg cells might also occur in vivo [13, 14].
However, the majority of studies report beneficial results from
transfer of Treg cell populations, indicating that in vivo processes
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can limit the risk of these cells having detrimental proinflam-
matory effects [15]. Identifying these processes that might sta-
bilize Treg cell suppressive function would therefore improve the
chances of successful translation to the clinic.
We have previously described that TGF-β-induced iTreg cells do
not produce IL-17 under Th17 conditions, because of their intrin-
sic production of small quantities of IFN-γ during their generation
in vitro [16]. While this prevents the production of one proinflam-
matory cytokine (IL-17) the other consequence is that iTreg cells
are able to express T-bet and retain the ability to produce IFN-γ
under secondary TCR stimulation, and this is greatly enhanced if
that stimulation occurs in the presence of IL-12 [16]. In that pre-
vious study, we asked whether IL-12-conditioning would produce
T-bet+, IFN-γ-producing “ex-iTreg” cells that could drive autoim-
mune pathology. We found that myelin-responsive ex-iTreg cells
had a very poor ability to induce autoimmune CNS inflammation
(EAE) when transferred, compared to T-bet+, IFN-γ-producing
bona fide T effector (Teff) cells. That inability of ex-iTreg cells to
drive profound pathology might have reflected the fact that IFN-γ
is not a required cytokine for EAE pathology [17, 18].
Here, we sought to understand whether iTreg cells could
produce other proinflammatory cytokines and, if so, to identify
what might limit such a response. We show that iTreg cells can
also produce TNF-α and GM-CSF upon secondary stimulation in
vitro in the absence of any exogenous cytokines. This did not
impair their ability to suppress the activation of na¨ıve T cells,
either in vitro or in vivo. In contrast, upon receipt of TCR stim-
ulation under inflammatory conditions in vivo (immunization
with peptide in complete Freund’s adjuvant, CFA), iTreg main-
tained their ability to produce both IFN-γ and TNF-α, but GM-CSF
production was impaired.
Results
iTreg cells can produce IFN-γ, GM-CSF, and TNF-α
upon secondary TCR stimulation
iTreg cells were generated by 5 day culture of naive (Foxp3-GFP−
CD4+) T cells with anti-CD3, anti-CD28, TGF-β, and IL-2. Highly
pure iTreg cells were isolated by FACS-sorting based on Foxp3-GFP
expression, (Fig. 1A) andwere then restimulated with plate-bound
anti-CD3 and anti-CD28 for 72 h. We used cytokine bead arrays
to screen for the presence of inflammatory cytokines in super-
natants from these secondary cultures. The majority of cytokines
tested (IL-2, IL-4, IL-5, IL-6, IL-10, IL-13, IL-17, IL-21, and IL-22)
were undetectable (data not shown). However, IFN-γ, TNF-α,
and GM-CSF were detectable. Intracellular cytokine staining of
restimulated iTreg cells demonstrated the loss of Foxp3 expres-
sion, as previously described [16], and confirmed the presence of
cells staining positive for IFN-γ, GM-CSF, and TNF-α (Fig. 1B–E).
The majority of cells were TNF-α+ (Fig. 1D). Production of IFN-γ
and GM-CSF was more restricted, and approximately 25% of cells
were double positive for IFN-γ and GM-CSF (Fig. 1E). While IFN-γ
and GM-CSF staining was seen chiefly in cells that had lost Foxp3
Figure 1. TGF-β-induced Treg cells produce pro-inflammatory
cytokines IFN-γ, GM-CSF, and TNF-α. (A–E) iTreg cells were gener-
ated from CD4+Foxp3gfp− cells (from Foxp3LuciDTR-4 mice) by 5-day
culture as described in the Materials and methods. (A) Foxp3gfp expres-
sion pre and postsort on day 5 is shown. Numbers represent the per-
centage of Foxp3+ cells. (B–E) iTreg cells were then restimulated for 72 h
with plate-bound anti-CD3 and anti-CD28 prior to intracellular staining
for Foxp3 and cytokines and analysis by flow cytometry. Numbers on
plots refer to percentage in each quadrant, rounded to the nearest inte-
ger. Data shown are from a single experiment representative of three
experiments performed. (F–H) Tg4.Foxp3LuciDTR-4 iTreg cells (sorted
to >98% Foxp3gfp+ purity) were restimulated for 48 h in triplicate with
the indicated concentrations of MBP(Ac1–9) in the presence of splenic
APCs. Supernatants were analyzed by ELISA for production of (F) IFN-γ,
(G) GM-CSF, and (H) TNF-α. Data are shown asmean± SEM of triplicates
from one experiment representative of three experiments.
expression, TNF-α was also seen in a clear population that had
retained Foxp3.
Loss of Foxp3 expression by iTreg cells is widely described,
with the majority of cells here being Foxp3− by the end of the
72 h secondary stimulation. We have previously studied this rig-
orously and have shown that contaminating Foxp3− cells remain-
ing after FACS sorting at the end of the primary iTreg-generating
culture (here <1%) remain at the same frequency through to the
end of the secondary culture [16]. Therefore, these contaminating
C© 2014 The Authors. European Journal of Immunology published by
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Foxp3− cells could only account for 1% of cells in the culture at
the time we assessed cytokine production, and could not be the
source of the high frequencies of cytokine+ cells seen (Fig. 1B–E).
To be able to assay cytokine production in response to
APCs presenting cognate antigen, we generated iTreg cells from
Tg4.Foxp3.LuciDTR-4 mice, which express a transgenic TCR rec-
ognizing the Ac1–9 peptide of myelin basic protein (MBP). Super-
natants of cultures in which these iTreg cells were restimulated
using splenic APCs together with increasing concentrations of the
MBP peptide demonstrated dose-dependent cytokine production.
Of interest, TNF-α, and particularly GM-CSF production were evi-
dent at lower levels of TCR stimulation than were required for
IFN-γ production (Fig. 1F–H).
iTreg cells produce IFN-γ, GM-CSF, and TNF-α during
their primary generation
Cytokine production by iTreg cells was investigated further
during the initial Foxp3-induction culture. Of note, Foxp3-gfp
expression consistently increased to over 90% within 72 h
(Fig. 2A). At that time, cytokine production was low or unde-
tectable, but rose markedly in cultures sampled at days 4 and
5 (Fig. 2B–D). This argues against the possibility that the sole
source of IFN-γ, GM-CSF, and TNF-α was cells that had not gained
Foxp3 expression. This was further shown by clear populations of
cytokine+ Foxp3+ cells at the end of the 5-day culture (Fig. 2E–F).
This was particularly the case for TNF-α (Fig. 2F).
Blockade of IFN-γ, GM-CSF, or TNF-α does not alter
iTreg-cell suppressive function in vitro
Thus far we had demonstrated that iTreg cells generated using a
well characterized and widely used method would produce three
proinflammatory cytokines upon secondary stimulation. We asked
whether this would either diminish, or enhance, the strength of
iTreg cell function using in vitro assays for suppression of na¨ıve
T cell activation. Although production of all three cytokines was
again evident (data not shown), there was no apparent influ-
ence on the suppressive function of iTreg cells upon the prolifera-
tive response of naive T responder cells, stimulated by peptide-
bearing APCs. Antibody neutralization of individual cytokines
did not boost, or reduce, the observed suppression (Fig. 3A–C).
Furthermore, IFN-γ-deficient iTreg did not have enhanced, or
reduced, suppressive activity (Fig. 3D).
Despite proinflammatory cytokine production, iTreg
cells maintain suppressive activity in vivo
iTreg cells can therefore produce GM-CSF, IFN-γ, and TNF-α, as
well as showing expression of T-bet [16]. This phenotype is com-
monly seen in myelin-responsive CD4+ T cells that can induce
passive EAE upon adoptive transfer [19–21]. We have previously
Figure 2. Production of IFN-γ, GM-CSF, and TNF-α occurs during pri-
mary iTreg-cell generation. Naive CD4+Foxp3gfp− cells were cultured
in triplicate for 5 days in iTreg-cell conditions (IL-2 and TGF-β with
plate-bound anti-CD3 and anti-CD28). Cells and supernatants were
sampled daily. (A) The percentage of cells expressing Foxp3 as deter-
mined by intracellular Foxp3 staining and flow cytometry is shown.
(B–D) Supernatantswere analyzed by ELISA for the presence of (B) IFN-γ,
(C) GM-CSF, and (D) TNF-α. Data are shown asmean± SEM of triplicates
from one experiment representative of three experiments. (E–G) Flow
cytometry at the end of iTreg-cell culture (day 5) showing intracellular
staining for Foxp3 and (E) IFN-γ, (F) GM-CSF, and (G) TNF-α. Numbers
on plots refer to percentage in each quadrant rounded to the nearest
integer.
reported only very poor pathogenic activity with “ex-iTreg” cells
(which in that case had received a second stimulation in the
presence of IL-12 to further boost T-bet expression and IFN-γ
production) [16]. However, we reasoned that those cells might
have had reduced GM-CSF production, due to the inhibitory
effect of IL-12 [20]. Given that T cell production of GM-CSF
(and not IFN-γ) is now believed to be essential for EAE induc-
tion [17, 18, 20, 22, 23], we revisited this issue, by testing the
pathogenic activity of GM-CSF-producing primary iTreg cells (not
exposed to IL-12). Using MBP-responsive iTreg cells generated
from Tg4.Foxp3LuciDTR-4 mice, we found that transfer of these
cells did not provoke clinical signs of EAE (Fig. 4A). Moreover,
we confirmed the maintained suppressive activity of these autore-
active iTreg cells, because their cotransfer alongside naive Tg4 T
responder cells into C57BL/6 × B10.PL mice prevented EAE upon
subsequent immunization with the MBP peptide in CFA (Fig. 4B).
The donor T responder cell population was distinguishable
by its unique expression of CD90.1, allowing assessment of the
C© 2014 The Authors. European Journal of Immunology published by
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Figure 3. Production of IFN-γ, GM-CSF, and TNF-α is nonessential
for iTreg-cell suppressive capacity. Varied numbers of iTreg cells
were cocultured with a fixed number of naı¨ve T responder cells as
described in the Materials and methods. Proliferation was quantified by
3 H-thymidine incorporation after 96 h culture. Percent suppression
was calculated, based on the means of triplicate cultures, following the
addition, at the onset of co-culture, of (A) anti-TNF-α, (B) anti-GM-CSF,
and (C) anti-IFN-γ. Filled triangles: anti-cytokine, open squares: isotype
control antibodies. (D) The suppressive capacity of iTreg cells generated
from Tg4.IFN-γ–/– mice were compared with that of iTreg cells gener-
ated from Tg4.CD90.1 (Tg4.WT) mice in suppression assays using naı¨ve
CD4+ Tg4 cells stimulated with MBP Ac1–9 and splenic APCs. Data are
from one experiment representative of two experiments.
effects of iTreg cells upon their naive counterparts (Fig. 4C–G).
The presence of iTreg cells limited the numbers and frequen-
cies of T responders found in the draining lymph nodes sampled
7 days after immunization (Fig. 4C, D). Interestingly, comparison
of cytokine production by the T responder population revealed
that it was only the frequencies of IFN-γ+ (not TNF-α+ or
GM-CSF+) cells that were diminished in this population when
iTreg cells were also administered (Fig. 4E–G). However, the sig-
nificantly lower numbers of T responders (Fig. 4D) meant that
total numbers of all cytokine+ T responders were lower when
iTreg cells were present in the priming lymph node. We there-
fore concluded that the suppressive effects of iTreg cells upon T
responders can proceed in vivo despite the ability of iTreg cells to
produce IFN-γ, GM-CSF, and TNF-α.
iTreg cells do not produce GM-CSF when stimulated
under inflammatory conditions in vivo
To justify the above conclusion, we performed experiments to
confirm that iTreg cells maintained their ability to produce
cytokines in the in vivo inflammatory setting used (immunization
with cognate peptide in the presence of CFA). Tg4.Foxp3LuciDTR-
4 iTreg cells were transferred alone, with immunization the fol-
lowing day. Donor iTreg cells (identified by expression of CD45.1)
sampled 7 days later had largely lost Foxp3 expression, but
Figure 4. Autoantigen-responsive iTreg cells are suppressive rather
than pathogenic and selectively lose the ability to produce GM-CSF
in response to antigen in an inflammatory context. (A) Clinical course
of passive EAE in C57BL/6 x B10.PL mice (five per group) that received
either CD4+ effector cells (4 × 106/mouse) or iTreg cells (6 × 106/mouse)
generated from naı¨ve Tg4.Foxp3LuciDTR-4 T cells wasmonitored daily.
(B) Clinical course of active EAE in C57BL/6 x B10.PLmice (five per group)
that received 1 × 106 naı¨ve CD4+ Tg4 cells, either alone, or together
with an equal number of Tg4 × Foxp3LuciDTR-4 iTreg cells, one day
before immunization with MBP peptide, was monitored daily. Data are
shown as mean ± SEM of the indicated number of mice from single
experiments representative of two performed. (C–G) C57BL/6 × B10.PL
mice (four per group) received 2 × 106 naı¨ve CD4+ Tg4.CD90.1 cells,
either alone (–) or together with an equal number of Tg4.Foxp3LuciDTR-
4 iTreg cells (+), one day before immunization with MBP peptide. After
7 days, draining lymph nodes were analyzed by flow cytometry for
(C and D) the presence of the transferred naı¨ve CD4+ Tg4.CD90.1 cells
and (E–G) the ability of those cells to produce (E) IFN-γ, (F) GM-CSF,
and (G) TNF-α after overnight culture of lymph node cells with the
MBP peptide. Each data point represents an individual mouse and data
shown are from single experiments representative of three performed.
*p < 0.05 as determined by Mann–Whitney U test; ns = not signifi-
cant. (H–J) B10.PL mice received 2 × 106 Tg4 × Foxp3LuciDTR-4 iTreg
cells alone one day before immunization with the MBP peptide as
above. After 7 days, spleens were harvested and cultured and stained
for cytokine production as above. Plots are gated on CD45.1+ donor
iTreg cells (for gating strategy, see Supporting Information Fig. 2) show-
ing expression of Foxp3 and production of (H) IFN-γ, (I) TNF-α, and
(J) GM-CSF. Numbers on plots refer to percentage in each quadrant,
rounded to the nearest integer. Data shown are from a single experi-
ment representative of three performed.
C© 2014 The Authors. European Journal of Immunology published by
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maintained the ability to produce IFN-γ and TNF-α (Fig. 4H, I). In
contrast, their ability to produce GM-CSF was markedly impaired
(Fig. 4J). Analysis of host CD4+ cells confirmed the presence of
Foxp3− GM-CSF+ cells, demonstrating that this finding was not
due to technical failure of anti-GM-CSF staining.
iTreg cells remain suppressive following secondary
stimulation, despite loss of Foxp3 expression
The data above indicated that the iTreg-cell population was sup-
pressive following in vivo immunization (Fig. 4B) despite largely
losing Foxp3 expression (Fig. 4H–J). We sought to test whether
this was due to retained suppressive activity in cells that had lost
Foxp3, or to overriding suppression provided by a minor popula-
tion that had maintained Foxp3. iTreg cells were generated and
subjected to secondary TCR stimulation in vitro. As seen above
(Fig. 1), this drove the loss of Foxp3-GFP expression in a propor-
tion of cells, allowing us to sort into GFP+ and GFP− populations
(Supporting Information Fig. 1). These were then tested in in
vitro suppression assays. Inhibition of the proliferation of respon-
der cells was equivalent regardless of the GFP status of the iTreg
cells used (Supporting Information Fig. 1C). We conclude that
iTreg cells can maintain suppressive activity once Foxp3 is lost, at
least for the duration of an in vitro suppression assay.
Exposure to cytokines inhibits the ability of iTreg cells
to produce GM-CSF
The results in Fig. 4H–J suggested that component(s) of the in
vivo inflammatory milieu were capable of selectively degrading
the ability of iTreg cells to produce GM-CSF while maintaining
IFN-γ and TNF-α production. To understand whether inflamma-
tory cytokine(s) might be responsible for this, we returned to the
in vitro restimulation of iTreg cells either under “neutral” condi-
tions, or in the presence of additional cytokines (Fig. 5).

Figure 5. Proinflammatory cytokines can selectively impair the pro-
duction of GM-CSF by iTreg cells. (A–D) Sorted (>99% Foxp3gfp+) iTreg
cells were restimulated with plate-bound anti-CD3 and anti-CD28 (both
2 μg/mL) with the addition of IL-12 (25 ng/mL), IL-27 (10 ng/mL), IL-6
(30 ng/mL), or IL-1β (10 ng/mL) for 72 h, with brefeldin A, PMA, and
ionomycin for the final 4 h of culture. Cytokine production was then
assessed by intracellular staining. (A) Representative flow cytometry
plots of cytokine production by iTreg cells gated on live CD4+ cells
(for gating strategy, see Supporting Information Fig. 3). Numbers on
plots refer to percentage in each quadrant, rounded to the nearest inte-
ger. (B–D) Summary data for the proportion of restimulated iTreg cells
producing (B) IFN-γ, (C) GM-CSF, and (D) TNF-α are shown as mean +
SEM of triplicates. (E–G) iTreg cells were restimulated in the presence
or absence of additional IL-2 (100 U/mL) and/or TGF-β (5 ng/mL), then
analyzed as above. Summary data show the proportion of iTreg cells
producing (E) IFN-γ, (F) GM-CSF, and (G) TNF-α are shown as mean ±
SEM of triplicates. All data are from one experiment representative
of three independent experiments. (H) iTreg cells were stained at the
end of the 5-day Foxp3-induction culture for the expression of gp130
and CD126 (open histograms). Filled histograms show isotype control
staining. Naı¨ve T cells were also stained.
C© 2014 The Authors. European Journal of Immunology published by
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Figure 6. Differential influence of IL-6, IL-12, and IL-27 upon cytokine
production by Th0, Th1, and iTreg cells. Th0, Th1, and iTreg cells were
generated from naive CD4+ Tg4.Foxp3LuciDTR-4 cells. Prior to restimu-
lation, cells were FACS-sorted as GFP+ (for iTreg cells) or GFP− (for Th0
and Th1 cells). Cells were then restimulated for 48 h in triplicate with
B10.PL splenic APCs and a dose response of MBP(Ac1–9) peptide with
or without the addition of IL-6 (30 ng/mL), IL-12 (25 ng/mL), or IL-27
(50 ng/mL). Supernatants were analyzed by ELISA for production of the
indicated cytokines. Data are shown as mean ± SEM of triplicates from
one experiment representative of two experiments.
Inclusion of IL-1β did not modify cytokine production by iTreg
cells (Fig. 5A–D). Both IL-12 and IL-27 are known to inhibit
GM-CSF production, but to promote/maintain IFN-γ production,
by CD4+ T cells [20, 24]. We found that addition of either of
these cytokines could specifically suppress GM-CSF, but not IFN-γ
or TNF-α, recapitulating the ex vivo response profile of iTreg cells
following immunization (Fig. 5A–D). Increased frequencies of
IFN-γ+ cells seen in iTreg cells restimulated in the presence of
IL-12 (Fig. 5A and B) were consistent with our previous obser-
vations [16]. Inclusion of IL-6 in iTreg-cell restimulation cultures
also reduced the frequencies of GM-CSF+ cells (Fig. 5A and C).
Inflamed lymph nodes contain other cytokines relevant to Treg
cells, in particular IL-2 and TGF-β. Inclusion of IL-2 alone did
not alter the frequencies of cells staining for either of the three
cytokines of interest (Fig. 5E–G). In contrast, the known sup-
pressive effects of TGF-β on IFN-γ production were evident in
these iTreg cell cultures (Fig. 5E). Inclusion of TGF-β also lowered
the frequencies of GM-CSF+ cells (Fig. 5F), but had no effect on
TNF-α+ frequencies (Fig. 5G). Inclusion of IL-2 and TGF-β together
restored IFN-γ (Fig. 5E), but did not restore GM-CSF expression.
Consistent with their sensitivity to IL-6 (Fig. 5A and C), iTreg
cells expressed both chains of the IL-6 receptor (gp130 and
CD126), albeit to lower levels than found on naive CD4+ T cells
(Fig. 5H).
Proinflammatory cytokines differentially affect
cytokine production by Th0, Th1, and iTreg cells
We addressed whether the inhibitory effects of IL-6, IL-12, and
IL-27 upon cytokine production were a unique feature of iTreg
cells, or were common to other CD4+ T cell populations capa-
ble of producing IFN-γ, GM-CSF, and TNF-α (Fig. 6). For this
comparison, iTreg, Th0, and Th1 cells were generated from na¨ıve
Tg4.Foxp3LuciDTR-4 cells and restimulated with splenic APCs and
a dose response of MBP peptide. In the absence of exogenous
cytokines, iTreg cells produced lower levels of GM-CSF and TNF-α
than their Th0 and Th1 counterparts. Levels of IFN-γ were simi-
lar between iTreg cells and Th0 cells and, as would be expected,
these were lower than those detected from Th1 cells (Fig. 6A–C).
Addition of either IL-6 or IL-27 inhibited iTreg-cell production of
GM-CSF (Fig. 6F), mirroring their effects seen with APC-free TCR
stimulation (in Fig. 5). However, inhibition of GM-CSF was not
seen with IL-12. GM-CSF production by iTreg cells and Th0 cells
was affected in a similar way by exogenous cytokines (Fig. 6D and
F), whereas no clear inhibition of Th1-cell production of GM-CSF
was evident (Fig. 6E). The only cytokine to clearly elevate IFN-γ
production by iTreg cells was IL-12; IL-27 could not achieve this
(Fig. 6C). We conclude that, while there is some overlap in how
IL-6, IL-12, and IL-27 influence cytokine production by Th0, Th1,
and iTreg cells, each cell-type shows a unique response profile to
these cytokines.
Discussion
Despite having potent suppressive activity in vitro and in vivo, Treg
cells possess the ability to produce significant amounts of proin-
flammatory cytokines when stimulated in a range of inflammatory
milieu [15]. These concerns are compounded by the consistent
observations that, in in vivo models the most efficacious Treg cells
are those that recognize an antigen that is relevant to the disease
being studied, presumably because these Treg cells have an
improved capacity to reach the organ in which their antigen is con-
centrated and/or to persist there [1, 2]. In the therapeutic setting,
this organ would be inflamed and therefore the infiltrating Treg
cells would encounter cytokines that might promote their trans-
differentiation toward effector function. The therapeutic bene-
fit of antigen-specific Treg cells would be greatly outweighed
by the clinical risks if these cells became pathogenic, as further
organ destruction would seem almost inevitable. Understand-
ing this possible trans-differentiation of Treg cells thus assumes
C© 2014 The Authors. European Journal of Immunology published by
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great importance in ensuring their translation to the therapeutic
armamentarium.
Here, we extend our previous observation that iTreg cells
can produce significant amounts of IFN-γ [16], to show that
they also can produce two other potent inflammatory cytokines,
GM-CSF, and TNF-α. The production of these three proinflamma-
tory cytokines by iTreg cells is gained during their primary genera-
tion in the presence of TGF-β. Indeed, the concentration of all three
cytokines appears to coincide with the expression of Foxp3 in pri-
mary iTreg-cell cultures. Thus, the production of these cytokines
appears to be intrinsic to iTreg cells, rather than representing a loss
of their suppressive phenotype. Neutralization of either cytokine
did not impact on the ability of iTreg cells to suppress na¨ıve
T cells, at least within the systems investigated here. This raises the
question of whether there is a functional (suppressive) purpose to
the production of these cytokines by iTreg cells?
The intrinsic ability of iTreg cells to express T-bet and pro-
duce IFN-γ could be enhanced by exposure to IL-12 [16, 25].
Despite this, in our previous study we found that MBP-responsive
iTreg cells exposed to IL-12 could produce only very modest clin-
ical signs of CNS inflammation (far weaker than those provoked
by bona fide Teff cells expressing the same MBP-responsive TCR),
even when infused in relatively high numbers. In fact, those IFN-γ-
producing iTreg cells were able to suppress EAE driven by na¨ıve
MBP-responsive T cells following immunization [16]. Similarly,
microbiota-responsive IFN-γ+Foxp3+ iTreg cells failed to induce
colitis upon transfer to RAG−/− hosts, instead retaining suppres-
sive function, protecting against disease transferred by Foxp3−
T cells [25]. A protective role for IFN-γ and a contribution of this
cytokine to suppressive function in vivo has been suggested in a
skin graft tolerancemodel [26]. There, mice tolerized to skin grafts
by the infusion of alloantigen-responsive Treg cells rapidly rejected
the grafts following treatment with anti-IFN-γ. Human IFN-γ+
Foxp3+ Treg cells can suppress alloresponses in vitro and the
presence of elevated levels of IFN-γ+Foxp3+ T cells in peripheral
blood correlated positively with good long-term graft function fol-
lowing renal transplantation [27]. Elevated frequencies of IFN-γ+
Treg cells have also been identified in human patients with dia-
betes mellitus and these were shown to have suppressive function
in vitro [9]. Notably, those IFN-γ+Foxp3+ Treg cells lacked Helios
expression and showed incomplete demethylation of the Treg-
specific demethylation region within the Foxp3 promoter, indicat-
ing that they were peripherally generated (p)Treg cells [9]. The
induced coexpression of Foxp3 and IFN-γ therefore represents
an important element of naturally occuring immunoregulatory
networks rather than an in vitro artifact. IFN-γ has a protective role
in EAE [18], and Treg cells have a key suppressive function within
the inflamed CNS [28, 29]. However, we have previously reported
that Treg cells isolated from the inflamed CNS do not produce
IFN-γ [30], indicating that this cytokine is not a critical com-
ponent of their suppressive armory in that context. Indeed, oth-
ers have reported that production of IFN-γ by the EAE-initiating
T cells is important for determining EAE severity [31].
Treg cells have greater expression of TNF receptor 2 than other
activated T cells, and this may be correlated with their suppressive
function [32]. A crucial role for TNF-α has been suggested in
suppression by nTreg cells in a model of colitis in RAG–/– mice
[33]. Treg-cell function has been reported to be enhanced in the
presence of Teff cells, and this was partly mediated through Teff-
cell production of TNF-α [34]. Thus, iTreg cells may similarly boost
their own suppressive function in an autocrine fashion, although
here neutralization of TNF-α did not modify in vitro suppressive
function.
The recent reemphasis on GM-CSF as a key cytokine produced
by encephalitogenic T cells [20] gave a possible explanation for the
relative failure of IFN-γ-producing iTreg cells to produce pathol-
ogy [16] (IFN-γ is not required for EAE induction, but GM-CSF
is). IL-12-conditioning of iTreg cells elevated their production
of IFN-γ, but would diminish their ability to produce GM-CSF
(as shown here). However, administration of high numbers of
MBP-responsive iTreg cells, with a retained capability for GM-CSF
production, could not deliver clinical signs of autoimmune CNS
inflammation. Rather, they maintained profound suppressive
function. It was notable that suppressive iTreg cells largely lost
Foxp3 expression after transfer and immunization, analogous to
the loss of Foxp3 upon secondary in vitro stimulation. In the in
vitro scenario, iTreg cells that had lost Foxp3(GFP) were equally
suppressive as their Foxp3(GFP)+ counterparts. The in vivo exper-
imental system used was not amenable to verification of this,
but these data indicate that suppressive function of iTreg cells
can outlast their expression of Foxp3. Further detailed inves-
tigation will be needed to understand the basis and longevity
of this suppressive function in the absence of sustained Foxp3-
expression.
Our data indicate that, rather than gaining a proinflammatory
function, iTreg cells lose this capacity (at least to some extent)
when placed in an inflammatory environment. Following immu-
nization with myelin autoantigen in CFA, the myelin-responsive
naive T cells that go on to form encephalitogenic Teff cells rapidly
gain the ability to produce inflammatory cytokines, including
IFN-γ, TNF-α, and GM-CSF [35]. WhenMBP-responsive iTreg cells
were exposed to this in vivo inflammatory scenario, they
maintained their capacity to produce IFN-γ and TNF-α, but their
ability to produce GM-CSF was relatively degraded. In vitro exper-
iments showed that this phenotype could be replicated by several,
but not all, cytokines tested. Two of these, IL-1β and IL-2, when
given alone, did not alter the frequencies of iTreg cells making
IFN-γ, GM-CSF, or TNF-α. The documented reduction in GM-CSF
production by Teff cells exposed to IL-12 or IL-27 [24], could be
replicated in iTreg cells. IFN-γ and TNF-α were not grossly altered
by exposure IL-27, whereas IL-12 selectively elevated IFN-γ, as
we reported previously [16]. Exposure to IL-6 could also reduce
GM-CSF production while leaving IFN-γ and TNF-α intact. TGF-β
suppressed GM-CSF production, but also (as has been well doc-
umented for the control of Th1 responses [21, 36, 37]) greatly
reduced IFN-γ production (not a feature of iTreg cells exposed to
in vivo stimulation, in the inflamed lymph node). However, while
IL-2 alone had no effect on cytokine production by iTreg cells,
it could counteract the TGF-β-mediated inhibition of IFN-γ, but
not GM-CSF. Therefore, the altered cytokine profile displayed by
C© 2014 The Authors. European Journal of Immunology published by
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iTreg cells placed in an inflamed lymph node could be replicated
in vitro by exposure to IL-12 alone, IL-27 alone, IL-6 alone, or a
combination of TGF-β plus IL-2. All of these cytokines would be
present at elevated concentrations in an inflamed lymph node,
and most likely an inflamed tissue. Furthermore, the selective
inhibitory effect of IL-27 upon GM-CSF production (i.e. without
boosting IFN-γ production) by iTreg cells was not replicated in
Th0 or Th1 cells, which did show elevated IFN-γ production. IL-12
boosted IFN-γ production by iTreg cells, but only suppressed their
production of GM-CSF when TCR stimulation was provided in the
absence of APCs. This was unlikely to reflect a constitutive inhibi-
tion of GM-CSF by APC-derived IL-12, that could not be enhanced
by exogenous IL-12, since Th0 production of GM-CSF was inhib-
ited by IL-12 addition. The selective inhibition of cytokine produc-
tion by Treg cells under different inflammatory milieu warrants
further investigation.
The expression of cytokine receptors by T cells seems quite
dynamic, varying with stage of (and time since) activation. For
example, although IL-6 is entirely required for the induction of EAE
[38, 39], this is a transient requirement [40, 41] and by the time
T cells (both Teff and Treg cells) arrive in the CNS they are insen-
sitive to IL-6, having downregulated expression of both gp130
and CD126 [30]. Considering this point, the inhibitory effect of
IL-6 upon iTreg-cell production of GM-CSF was somewhat surpris-
ing, given a previous report describing enhanced loss of CD126 at
3 days following activation in primary iTreg-generating cultures
[6]. This difference is resolved by our observation that, at the time
of secondary stimulation, our iTreg cells did show expression of
gp130 and CD126. Whether this was a kinetic factor, i.e. the iTreg
cells had lost but then regained these receptor chains during the
5 days of culture, remains to be defined. Clearly iTreg cells express
receptors for IL-2 and TGF-β (both key to their generation) and
must also express receptors for IL-12 and IL-27, when exposed
to these cytokines in the cultures used here. We suggest that the
dynamic expression of cytokine receptors (not just by T cells)
during inflammation is a very important, but largely neglected
area of study. Furthermore, given our observations, investigations
into the stability of Treg cells should not use evidence of proin-
flammatory cytokine production as a surrogate for evidence of loss
of suppressive function.
Materials and methods
Mice, antigens, and tissue culture medium
C57BL/6, B10.PL, C57BL/6xB10.PL, Foxp3GFP, Foxp3LuciDTR-
4 [42], Tg4.CD90.1, and Tg4.Foxp3LuciDTR-4.CD45.1 [16]
mice were bred under specific pathogen-free conditions.
Tg4.CD45.1.IFN-γ−/− were generated by crossing IFN-γ–/– mice
with Tg4.CD45.1 [21] mice and backcrossing for ten generations.
Experiments received University of Edinburgh ethical approval
and were performed under UK. legislation (PPL 60/4116). The
acetylated 1–9 peptide of MBP (ASQKRPSQR) and the Ac1–
9(4Tyr) variant were synthesized by Cambridge Research Biomed-
icals (Cambridge, UK). Tissue culture medium was RPMI 1640
containing 10% heat-inactivated fetal calf serum (Sigma-Aldrich,
Poole, UK.), 2 mM L-glutamine, 100 U/mL penicillin, 100 μg/mL
streptomycin (all PAA Laboratories Ltd., Somerset, UK) and 50μM
2-β-mercaptoethanol (Gibco).
T-cell purification and iTreg-cell generation
CD4+ T cells were purified using magnetic cell sorting (autoMACS
Pro, Miltenyi Biotec, Bergisch Gladbach, Germany) as per theman-
ufacturer’s instructions, with or without subsequent FACS-sorting.
Na¨ıve CD4+Foxp3− T cells from Foxp3-reporter mice were iso-
lated and purified (routinely to >99% CD4+Foxp3−) by FACS-
sorting on a BD FACSARIA II (BD Biosciences, Franklin Lakes,
NJ). Na¨ıve CD4+ T cells from Tg4.CD45.1.IFN-γ–/– mice (lacking
a Foxp3-reporter) were purified using a na¨ıve CD4+ T cell iso-
lation kit (Miltenyi Biotec) as per the manufacturer’s instruc-
tions. Foxp3 expression was induced by stimulation with plate-
bound anti-CD3 + anti-CD28 (both at 2 μg/mL) for 5 days in
the presence of 100 U/mL IL-2 and 5 ng/mL recombinant human
TGF-β1 (R&D Systems, Minneapolis, MN). In some experiments,
daily aliquots of culture supernatants were sampled for detection
of cytokine production by ELISA. On day 5, Foxp3+ cells were
FACS-sorted by Foxp3-reporter expression (routinely to >99%
purity).
iTreg-cell suppression assays
Suppression assays were performed by culturing na¨ıve CD4+
T responder cells (2 × 104/well) for 96 h with increasing numbers
of iTreg in the presence of 1 × 105 irradiated (30 Gy) APCs (red
cell-lysed B10.PL or C57BL/6 × B10.PL splenocytes) and either
1 μg/mL anti-CD3 or 10 μM MBP Ac1–9 peptide. A 0.5 μCi 3H-
thymidine (Amersham Biosciences, Amersham, UK.) was added
for the final 16 h and incorporation measured by β-scintillation
counting (Wallac, Turku, Finland). Where indicated, 10 μg/mL of
the following antibodies were added individually at the onset of
culture: rat anti-mouse GM-CSF (clone MP1–22E9, BD Pharmin-
gen), rat anti-mouse TNF-α (clone G281–2626, BD Pharmin-
gen), mouse anti-IFN-γ (clone XMG1.2, Bioxcell, West Lebanon,
NH).
FACS analysis of cytokine production
Surface staining was performed prior to processing for Foxp3
staining using Foxp3 fix/perm buffers according to the man-
ufacturer’s instructions (e-bioscience). Cells were then stained
for intracellular cytokines and appropriate isotype controls.
The following antibodies and isotype controls were used
(all from eBioscience unless stated); anti-CD4-e450, anti-
CD4-AF700 (BD Biosciences), anti-CD90.1-allophycocyanin,
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anti-CD90.1-FITC, anti-CD45.1-PerCPCy5.5, anti-gp130-
allophycocyanin, anti-CD126-PE, anti-Foxp3-e450, anti-
Foxp3-FITC, anti-Foxp3-allophycocyanin, anti-IFN-γ-FITC,
anti- IFN-γ-allophycocyanin, anti-GM-CSF-PE (BD Biosciences),
anti-TNF-e450, anti-CD25-PE, anti-CD25-PerCPCy5.5 (BioLegend
UK), rat IgG1-(FITC/PE/allophycocyanin/e450/AF647), rat
IgG2a-(PE/e450/allophycocyanin/FITC/PerCPCy5.5), rat-IgG2b-
allophycocyanin, viability dye e780. Following acquisition (LSR
Fortessa, II BD Biosciences), analysis was performed using FlowJo
software (Treestar version 3.2.1.).
In some experiments cytokine production was determined
by intracellular staining immediately after the 5-day iTreg-cell
culture. Cells were incubated at 37°C in the presence of 50 ng/mL
PMA, 1 μg/mL ionomycin (Sigma), and 3 μg/mL brefeldin A
(eBioscience) for 4 h prior to staining.
In other experiments iTreg cells were restimulated by 72 h
culture for with anti-CD3 and anti-CD28 (both 2 μg/mL). Where
indicated, the following cytokines were added individually to trip-
licate wells: IL-12 25 ng/mL (R&D), IL-27 10 ng/mL (R&D), IL-6
30 ng/mL (Miltenyi), IL-23 30 ng/mL (R&D), IL-1β 10 ng/mL
(R&D), IFN-γ 100 ng/mL (BD), TGF-β 10 ng/mL (R&D), IL-2
100 U/mL.
Generation of Tg4 Th0 and Th1 cells
Th0 and Th1 populations were generated from
naive CD4+ Tg4.Foxp3LuciDTR-4 cells (FACS-sorted
CD4+CD62LhiCD25−Foxp3-GFP−) by 72 h stimulation with
plate-bound anti-CD3 + anti-CD28. Th0 cultures were sup-
plemented with 10 U/mL IL-2 and 10 μg/mL anti-IFN-γ. Th1
cultures were supplemented with 25 ng/mL IL-12, 25 ng/mL
IL-18, and 10 U/mL IL-2 (at 48 h, a further 20 U/mL IL-2 was
added). After 72 h, cells were replated with fresh culture medium
containing 10 U/mL IL-2 for a further 48 h, at which time cells
were FACS-sorted for GFP− cells.
Tg4 T cell responses to antigen
Tg4 iTreg, Th0, or Th1 cells (2 × 104/well) were stimulated
with increasing concentrations of the MBP (Ac1–9) peptide in the
presence of irradiated (30 Gy) splenic APCs (1 × 105/well). After
48 h supernatants were collected for analysis of cytokine produc-
tion by ELISA.
For ex vivo analysis of Tg4 T-cell (Tresponder or iTreg)
responses, lymphoid cell populations were cultured overnight with
10 μM MBP(Ac1–9) with the addition of brefeldin A for the final
4 h and processing for intracellular cytokine staining as above.
In vivo immunization and EAE induction
Host C57BL/6×B10.PL mice received an i.v. infusion of 1–2 × 106
na¨ıve CD4+ Tg4.CD90.1 T responder cells, or Tg4.Foxp3LuciDTR-4
.CD45.1 iTreg cells, either alone, or together at a 1:1 ratio. One day
later, mice were immunizedwith 10μg ofMBP Ac1–9(4Tyr) emul-
sified in CFA (containing 50μg heat-killedMycobacterium tubercu-
losisH37Ra) (Sigma) at a final volume of 100μL as described [16].
For priming experiments, lymphoid organs were isolated 7 days
after immunization. For EAE experiments host mice also received
200 ng pertussis toxin (Health Protection Agency, Porton Down,
UK) i.p. on the day of immunization and 2 days later. For passive
transfer of EAE, host C57BL/6× B10.PLmice received an i.v. injec-
tion of 4 × 106 CD4+ Tg4 effector T cells generated by primary in
vitro stimulation as described [21], or 6× 106 Tg4.Foxp3LuciDTR-
4.CD45.1 iTreg cells. Mice also received pertussis toxin as above.
Clinical signs of EAE were assessed as described [21].
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